Citadel Advisors’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.39M Sell
293,900
-182,700
-38% -$1.66M ﹤0.01% 5714
2025
Q4
$3.2M Sell
476,600
-14,300
-3% -$108K ﹤0.01% 5051
2025
Q3
$4.26M Sell
490,900
-25,400
-5% -$198K ﹤0.01% 4655
2025
Q2
$3.25M Buy
516,300
+4,700
+0.9% +$31.1K ﹤0.01% 4839
2025
Q1
$3.28M Sell
511,600
-203,100
-28% -$1.68M ﹤0.01% 4603
2024
Q4
$5.75M Sell
714,700
-358,300
-33% -$3.45M ﹤0.01% 3740
2024
Q3
$13.6M Buy
1,073,000
+78,700
+8% +$1.02M ﹤0.01% 2500
2024
Q2
$12.6M Buy
994,300
+464,900
+88% +$4.68M ﹤0.01% 2499
2024
Q1
$2.53M Sell
529,400
-493,800
-48% -$2.29M ﹤0.01% 5069
2023
Q4
$4.91M Sell
1,023,200
-245,500
-19% -$1.5M ﹤0.01% 3821
2023
Q3
$9.19M Buy
1,268,700
+187,800
+17% +$1.5M ﹤0.01% 2793
2023
Q2
$8.03M Sell
1,080,900
-934,300
-46% -$7.35M ﹤0.01% 2969
2023
Q1
$14M Buy
2,015,200
+76,400
+4% +$703K ﹤0.01% 2369
2022
Q4
$19.9M Buy
1,938,800
+689,700
+55% +$12.2M ﹤0.01% 1971
2022
Q3
$22.7M Sell
1,249,100
-284,200
-19% -$12.3M 0.01% 1754
2022
Q2
$78.9M Buy
1,533,300
+68,100
+5% +$3.53M 0.02% 717
2022
Q1
$108M Buy
1,465,200
+97,600
+7% +$8.7M 0.02% 618
2021
Q4
$196M Buy
1,367,600
+416,700
+44% +$71.6M 0.04% 357
2021
Q3
$197M Buy
950,900
+28,400
+3% +$6.26M 0.04% 343
2021
Q2
$196M Buy
922,500
+186,600
+25% +$34.2M 0.04% 325
2021
Q1
$133M Buy
735,900
+71,700
+11% +$14.3M 0.03% 451
2020
Q4
$74.1M Sell
664,200
-216,200
-25% -$23M 0.02% 711
2020
Q3
$95.4M Buy
880,400
+599,400
+213% +$73M 0.03% 485
2020
Q2
$23.4M Buy
281,000
+91,700
+48% +$3.51M 0.01% 1380
2020
Q1
$2.57M Buy
189,300
+128,500
+211% +$1.09M ﹤0.01% 3731
2019
Q4
$242K Sell
60,800
-109,500
-64% -$475K ﹤0.01% 7907
2019
Q3
$855K Buy
170,300
+149,700
+727% +$819K ﹤0.01% 5855
2019
Q2
$121K Sell
20,600
-570
-3% -$4.49K ﹤0.01% 8462
2019
Q1
$233K Buy
21,170
+7,575
+56% +$239K ﹤0.01% 7987
2018
Q4
$500K Buy
13,595
+8,330
+158% +$323K ﹤0.01% 6391
2018
Q3
$198K Buy
5,265
+3,915
+290% +$110K ﹤0.01% 8223
2018
Q2
$36K Sell
1,350
-3,330
-71% -$113K ﹤0.01% 8509
2018
Q1
$197K Buy
4,680
+720
+18% +$28.9K ﹤0.01% 7366
2017
Q4
$98K Sell
3,960
-1,150
-23% -$28.1K ﹤0.01% 7443
2017
Q3
$117K Buy
5,110
+255
+5% +$5.71K ﹤0.01% 6979
2017
Q2
$112K Sell
4,855
-925
-16% -$18.1K ﹤0.01% 6866
2017
Q1
$148K Sell
5,780
-8,915
-61% -$245K ﹤0.01% 6693
2016
Q4
$370K Sell
14,695
-11,350
-44% -$331K ﹤0.01% 5366
2016
Q3
$1.08M Buy
26,045
+13,770
+112% +$1.78M ﹤0.01% 3738
2016
Q2
$1.78M Buy
12,275
+5,065
+70% +$580K ﹤0.01% 2871
2016
Q1
$744K Buy
7,210
+555
+8% +$59.5K ﹤0.01% 3844
2015
Q4
$1.12M Buy
6,655
+1,080
+19% +$166K ﹤0.01% 3431
2015
Q3
$788K Sell
5,575
-320
-5% -$71.8K ﹤0.01% 4146
2015
Q2
$1.31M Sell
5,895
-210
-3% -$36.9K ﹤0.01% 3608
2015
Q1
$1.01M Buy
6,105
+3,655
+149% +$593K ﹤0.01% 3908
2014
Q4
$291K Sell
2,450
-1,180
-33% -$123K ﹤0.01% 5486
2014
Q3
$303K Sell
3,630
-400
-10% -$36.2K ﹤0.01% 5250
2014
Q2
$372K Buy
4,030
+2,505
+164% +$220K ﹤0.01% 4766
2014
Q1
$138K Buy
1,525
+185
+14% +$20.7K ﹤0.01% 5878
2013
Q4
$137K Buy
1,340
+55
+4% +$3.89K ﹤0.01% 5354
2013
Q3
$81K Buy
1,285
+995
+343% +$56K ﹤0.01% 5485
2013
Q2
$12K Buy
+290
New +$12.6K ﹤0.01% 6195

Other funds holding NVAX

Citadel Advisors's NVAX Position: Q1 2026 in Review

Citadel Advisors increased its Novavax (NVAX) stake by 4.7% in Q1 2026, buying an estimated $453K and bringing the position to 1,123,746 shares worth $9.15M. The position accounts for ﹤0.01% of the portfolio, ranked #3379.

Citadel Advisors first reported a position in NVAX in Q2 2013 and has held it in 49 quarters since. The position peaked at $145M in Q2 2021. 257 funds tracked by Wall St. Rank hold NVAX as of Q1 2026.

  • Citadel Advisors held 1,123,746 shares of Novavax worth $9.15M as of Q1 2026.
  • Citadel Advisors bought 50,019 Novavax shares in Q1 2026, an estimated $453K.
  • Novavax made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3379 holding.
  • Citadel Advisors first reported a position in Novavax in Q2 2013 and has held it in 49 quarters since.
  • Citadel Advisors's Novavax position peaked at $145M in Q2 2021.
  • 257 funds tracked by Wall St. Rank held Novavax as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.